Kamada Ltd. (NASDAQ:KMDA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
A number of other equities analysts also recently weighed in on the stock. TheStreet raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Monday, September 26th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Kamada in a report on Saturday, September 3rd. Finally, Jefferies Group reiterated a “buy” rating and issued a $7.00 price objective on shares of Kamada in a report on Wednesday, August 31st.
Shares of Kamada (NASDAQ:KMDA) opened at 5.0899 on Wednesday. Kamada has a one year low of $3.26 and a one year high of $5.34. The company’s market capitalization is $185.36 million. The company has a 50-day moving average price of $4.76 and a 200 day moving average price of $4.08.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.04) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.04). Kamada had a negative net margin of 9.92% and a negative return on equity of 10.59%. The business had revenue of $19.10 million for the quarter, compared to the consensus estimate of $18.50 million. On average, analysts forecast that Kamada will post ($0.19) EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Kamada during the second quarter worth about $1,701,000. Vanguard Group Inc. boosted its stake in shares of Kamada by 19.0% in the second quarter. Vanguard Group Inc. now owns 327,533 shares of the company’s stock worth $1,202,000 after buying an additional 52,195 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Kamada by 2.4% in the first quarter. Renaissance Technologies LLC now owns 170,300 shares of the company’s stock worth $652,000 after buying an additional 4,000 shares in the last quarter. Hedge funds and other institutional investors own 5.31% of the company’s stock.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.